COCP
Cocrystal Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.13
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 330.0K | — | — | — | — |
| Cost of Revenue | (349.0K) | 5.1M | 12.5M | 15.2M | 12.4M |
| Gross Profit | 679.0K | (5.1M) | (12.5M) | (15.2M) | (12.4M) |
| Operating Expenses | |||||
| R&D Expense | 6.1M | 5.1M | 12.5M | 15.2M | 12.4M |
| SG&A Expense | 4.4M | 4.0M | 5.3M | 6.0M | 5.7M |
| General & Admin Expense | 4.4M | 4.0M | 5.3M | 6.0M | 5.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 349.0K | (5.1M) | (12.5M) | (17.8M) | 8.3M |
| Total Operating Expenses | 10.8M | 4.0M | 5.3M | 3.4M | 26.4M |
| Cost and Expenses | 10.4M | 9.0M | 17.9M | 18.6M | 38.8M |
| Operating Income (EBIT) | (10.1M) | (9.0M) | (17.9M) | (18.6M) | (38.8M) |
| Non-Operating | |||||
| Interest Income | (33.0K) | 134.0K | 537.0K | 640.0K | 2.00 |
| Interest Expense | — | — | — | — | 2.0K |
| Net Interest Income | (33.0K) | 134.0K | 537.0K | 640.0K | (2.0K) |
| Other Non-Op Income/Expense | 172.0K | 188.0K | 374.0K | 575.0K | (8.0K) |
| Non-Operating Income (excl Interest) | (172.0K) | (188.0K) | (374.0K) | 2.6M | (20.7M) |
| EBT (Pre-Tax Income) | (9.9M) | (8.8M) | (17.5M) | (18.0M) | (38.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (9.9M) | (8.8M) | (17.5M) | (18.0M) | (38.8M) |
| Earnings from Cont. Ops | (9.9M) | (8.8M) | (17.5M) | (18.0M) | (38.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (9.9M) | (8.8M) | (17.5M) | (18.0M) | (38.8M) |
| Per Share | |||||
| Basic EPS | ($0.77) | ($0.78) | ($1.72) | ($0.00) | ($4.77) |
| Diluted EPS | ($0.77) | ($0.78) | ($1.72) | ($0.00) | ($4.77) |
| Revenue Per Share | $0.02 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 13.8M | 11.3M | 10.2M | 9.7M | 8.1M |
| Diluted Shares Outstanding | 13.8M | 11.3M | 10.2M | 9.7M | 8.1M |
| Profitability Metrics | |||||
| EBITDA | (9.5M) | (8.5M) | (17.4M) | (21.0M) | (18.0M) |
| D&A | 445.0K | 376.0K | 126.0K | 189.0K | 185.0K |
| EBIT | (9.9M) | (8.8M) | (17.5M) | (21.2M) | (18.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026